NEQASNational External Quality Assessment Service (UK)
NEQASNational External Quality Assurance Scheme (est. 1969; UK)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
A multicenter ring study was conducted to assess the assay performance of the HER2 Dual ISH application by The United Kingdom National External Quality Assessment Service for Immunocytochemistry (UK NEQAS), and a high concordance rate between the bright-field and dark-field HER2 assays for diagnosing HER2 status was demonstrated.
Over the three year (2007-2009) review period, the laboratory routinely participated in two EQA programmes for anti-ENA detection, namely the rheumatic disease module from the Immunology RCPA (Australia) and the nuclear and related antigen module issued by UK NEQAS (England).
This is different than in the UK NEQAS and NordicQC PT programs, which involve central review of slides stained for human epidermal growth factor receptor type 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR).
(1) Among many other elements, the guideline mandates include assay validation and revalidation with demonstration that "positive ER or PgR categories are 90% concordant and negative ER or PgR categories are 95% concordant" (in comparison with clinically validated assays), (1,25) as well as ongoing proficiency testing, at least twice a year, with satisfactory performance defined as "90% correct responses on graded challenges." (1) Proficiency testing data allow analysis of assay variables from large numbers of participant laboratories; in fact, the UK Neqas program first drew attention to problematic (false positive) staining with the PgR rabbit monoclonal SP2.
The laboratory participates in the external quality assurance program of the UK NEQAS for Peptide Hormones (Edinburgh); laboratory biases were [less than or equal to] 2.5% (mean 0.4%) for 6 consecutive samples that had GH concentrations of 0.22-0.52 ng/mL, near the cutpoint of 0.4 ng/mL used for the GH suppression test.
(33.) UK NEQAS ICC & ISH Immunocytochemistry Journals.
Technical aspects of predictive and prognostic markers in breast cancer: what UK NEQAS data shows.
UK NEQAS Web site: 2014;